Home › Lung Cancer › Virginia › Charlottesville
Lung Cancer clinical trials in Charlottesville, VA
13 studies for Lung Cancer are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- University of Virginia Cancer Center, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- and 1 more
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- University of Virginia Health System, Charlottesville
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RecruitingPhase 1/2
- University of Virginia Cancer Center, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Sentara Martha Jefferson Hospital, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- University of Virginia, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- University of Virginia Cancer Center, Charlottesville
4D-MRI for Precision Medicine
RecruitingObservational studyHealthy volunteers welcome
- University of Virginia, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- University of Virginia Cancer Center, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Charlottesville
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Charlottesville
- Non-Small Cell Lung Cancer21 studies
- Acute Myeloid Leukemia16 studies
- Prostate Cancer15 studies
- Metastatic Cancer13 studies
- Endometrial Cancer13 studies
- Cancer (all types)13 studies
- Heart Failure11 studies
- Ovarian Cancer10 studies
- Colorectal Cancer10 studies
- Type 1 Diabetes9 studies
- Breast Cancer9 studies
- Pancreatic Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.